ARHGAP32 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 human colorectal adenocarcinoma cell line. This heterogeneous pool of gene-disrupted cells offers a loss-of-function model for studying ARHGAP32, a Rho GTPase-activating protein that negatively regulates Rho family GTPases. Without requiring single-cell cloning, the polyclonal format provides a robust system for functional screening and pathway analysis directly within an intestinal epithelial context.
The HT29 parental cell line originates from a primary colorectal adenocarcinoma of a 44-year-old female and is widely employed as a model for intestinal epithelial biology, colorectal cancer progression, and differentiation. HT29 cells are characterized by their epithelial morphology and capacity to differentiate under appropriate conditions, making them particularly relevant for examining processes such as epithelial-mesenchymal transition and tumor cell motility.
ARHGAP32 functions by accelerating GTP hydrolysis on Rho GTPases including RhoA, Rac1, and Cdc42, thereby inactivating downstream effectors such as ROCK, PAK, and LIMK. This GAP activity is critical for controlling actin stress fiber formation, focal adhesion turnover, and cell migration. ARHGAP32 interacts with RhoA, Rac1, Cdc42, Fyn kinase, PSD-95, and paxillin, and its expression is regulated by upstream TGF-?? and Wnt/??-catenin signaling. Loss of ARHGAP32 results in sustained RhoA and Rac1 activation, leading to enhanced MRTF/SRF transcriptional responses and altered cytoskeletal dynamics.
In the HT29 colorectal cancer context, ARHGAP32 knockout promotes persistent activation of RhoA and Rac1, which increases stress fiber assembly and cellular contractility while disrupting E-cadherin?Cmediated adhesion and integrin signaling. These alterations drive enhanced migration and invasion, mirroring aggressive colorectal cancer phenotypes. The model thus enables dissection of ARHGAP32’s role as a potential tumor suppressor and facilitates the study of Rho GTPase-driven mechanisms in metastasis.
These polyclonal knockout cells are suitable for diverse applications, including Rho GTPase activity pull-down assays, western blotting for RhoA, Rac1, and Cdc42, phalloidin-based actin staining, scratch wound migration, and Transwell invasion assays. Researchers can also employ the model for drug response profiling, co-immunoprecipitation of interacting proteins, RT-qPCR analysis of MRTF/SRF target genes, and phospho-signaling studies. For additional technical information, please contact Ascent Research.
